Clinical trial statistics are tightening into a measurable science, with the decentralized trials market expected to grow at a 25.8% CAGR from 2021 to 2028 and ClinicalTrials.gov listing 482,000+ registered studies and 49,000+ completed studies with posted results as of 2024. Yet behind the growth are sharp frictions that can derail outcomes, from FDA warning letters that can extend to trial documentation and compliance to protocol deviations reported in 50%+ of randomized trials. This post connects those moving parts into the numbers that shape how trials start, run, and report.
Key Takeaways
- The global clinical trials market was valued at $58.2 billion in 2021
- 38.3% of global CRO services revenue is expected to come from clinical monitoring in 2024, reflecting continued outsized demand for monitoring support
- The global electronic data capture (EDC) market is expected to reach $5.1 billion by 2029, driven by wider adoption in clinical trial data management
- In the EU, the start of clinical trials is governed by assessment through the EU portal and database under CTR Regulation (EU) No 536/2014
- The U.S. has a single structured submission system for clinical trial registration and results via ClinicalTrials.gov (final rule requires results reporting for applicable trials)
- In the U.S., results for applicable clinical trials must be submitted within 12 months after primary completion date (FDAAA 801; timing requirement)
- ClinicalTrials.gov contained 482,000+ registered studies as of 2024
- ClinicalTrials.gov listed 49,000+ completed studies with posted results as of 2024
- The global CRO market is projected to grow at a CAGR of 8.7% from 2024 to 2030
- 4.5% of all investigational new drug (IND) applications were placed on clinical hold in 2020 (US FDA data), reflecting a measurable gating step before trials start
- In FY 2023, FDA reported 1,391 human drug inspections, which include inspections relevant to clinical trial conduct and GCP compliance
- FDA issued 7,847 warning letters related to drugs in 2023, many of which include issues that can extend to clinical trial documentation and compliance
- From 2017 to 2022, 50%+ of randomized trials in a published benchmarking study reported protocol deviations of at least one type, indicating deviations are common
- A systematic review found that electronic consent (eConsent) adoption is associated with higher patient engagement metrics in 6 of 8 included studies (2019–2022 evidence synthesis)
- In a randomized evaluation of centralized eSource vs paper, median data entry time was reduced by 48% (2018 study)
With rising demand for faster, decentralized, and better compliant trial execution, CROs and data tools are scaling fast.
Related reading
01 · Category
Market Size5 stats
01
The global clinical trials market was valued at $58.2 billion in 2021
02
38.3% of global CRO services revenue is expected to come from clinical monitoring in 2024, reflecting continued outsized demand for monitoring support
03
The global electronic data capture (EDC) market is expected to reach $5.1 billion by 2029, driven by wider adoption in clinical trial data management
04
The global clinical trial imaging services market is forecast to grow to $4.6 billion by 2028, reflecting increasing use of imaging endpoints in late-stage trials
05
The global clinical trial recruitment market is projected to reach $5.0 billion by 2030, supported by sponsor demand for faster recruitment
Interpretation
Market Size Interpretation
In the Market Size landscape, clinical trial services are set for steady expansion, with the global clinical trials market reaching $58.2 billion in 2021 and key demand-driving segments projected to grow further such as EDC to $5.1 billion by 2029, imaging services to $4.6 billion by 2028, and recruitment to $5.0 billion by 2030.
02 · Category
Regulatory Environment3 stats
01
In the EU, the start of clinical trials is governed by assessment through the EU portal and database under CTR Regulation (EU) No 536/2014
02
The U.S. has a single structured submission system for clinical trial registration and results via ClinicalTrials.gov (final rule requires results reporting for applicable trials)
03
In the U.S., results for applicable clinical trials must be submitted within 12 months after primary completion date (FDAAA 801; timing requirement)
Interpretation
Regulatory Environment Interpretation
Across regulatory environments, the U.S. is enforcing faster results accountability with submissions due within 12 months after primary completion, while the EU centralizes trial starts through the EU portal and database under the CTR Regulation (EU) No 536/2014 and the U.S. uses a single structured system via ClinicalTrials.gov.
03 · Category
Industry Trends11 stats
01
ClinicalTrials.gov contained 482,000+ registered studies as of 2024
02
ClinicalTrials.gov listed 49,000+ completed studies with posted results as of 2024
03
The global CRO market is projected to grow at a CAGR of 8.7% from 2024 to 2030
04
The decentralized clinical trials market is expected to grow at a CAGR of 25.8% from 2021 to 2028
05
Mobile Health (mHealth) adoption in clinical trials reached 40% of surveyed sponsors by 2022 (industry survey, 2022)
06
63% of sponsors reported using decentralized elements (e.g., telehealth, remote visits, mobile/pharmacy) in at least one active study in 2022, according to a 2023 survey by Amplify
07
In a 2023 FDA inspection trends analysis published by a reputable legal/compliance publication, 36% of GCP inspection observations involved documentation and data integrity issues
08
A 2020 study found that clinical trial recruitment is a major delay driver, with enrollment delays accounting for a significant portion of total trial timeline variance (quantified in the paper)
09
A 2020 review reported that patient diversity gaps remain substantial, with underrepresentation of certain populations in trial enrollment relative to disease prevalence quantified in multiple included studies
10
A 2022 publication reported that women are underrepresented across clinical trials in selected therapeutic areas, quantified as a percentage difference between trial enrollment and population representation
11
2023 data from the OECD reported that health spending accounted for about 9.2% of GDP on average across OECD countries, setting macro context for healthcare-funded clinical research investment priorities
Interpretation
Industry Trends Interpretation
Industry Trends point to a fast-evolving clinical research ecosystem, with ClinicalTrials.gov reaching over 482,000 registered studies in 2024 and decentralized approaches accelerating as sponsors increasingly adopt them, including 63% using decentralized elements in at least one active study in 2022 and the decentralized clinical trials market projected to grow at a 25.8% CAGR from 2021 to 2028.
More related reading
04 · Category
Regulatory Compliance5 stats
01
4.5% of all investigational new drug (IND) applications were placed on clinical hold in 2020 (US FDA data), reflecting a measurable gating step before trials start
02
In FY 2023, FDA reported 1,391 human drug inspections, which include inspections relevant to clinical trial conduct and GCP compliance
03
FDA issued 7,847 warning letters related to drugs in 2023, many of which include issues that can extend to clinical trial documentation and compliance
04
EU GDPR requires “appropriate technical and organisational measures,” and clinical trials controllers must conduct data protection impact assessments (DPIAs) in high-risk processing cases per Article 35
05
The ICH E9(R1) addendum updates statistical principles for estimands and trial analysis, including explicit estimand specification requirements
Interpretation
Regulatory Compliance Interpretation
In regulatory compliance terms, FDA action is consistently concentrated before and during trial execution, with 4.5% of INDs placed on clinical hold in 2020 and 1,391 human drug inspections in FY 2023, while warning letters climbed to 7,847 in 2023 and GDPR DPIAs for high risk trial data processing add further governance pressure.
05 · Category
Performance Metrics10 stats
01
From 2017 to 2022, 50%+ of randomized trials in a published benchmarking study reported protocol deviations of at least one type, indicating deviations are common
02
A systematic review found that electronic consent (eConsent) adoption is associated with higher patient engagement metrics in 6 of 8 included studies (2019–2022 evidence synthesis)
03
In a randomized evaluation of centralized eSource vs paper, median data entry time was reduced by 48% (2018 study)
04
In a published meta-analysis, decentralized trial designs improved recruitment speed with a pooled estimate indicating a statistically significant reduction in time-to-enroll (2020–2022)
05
A 2022 paper reported that remote monitoring can reduce on-site monitoring visits by a median of 30% compared with traditional schedules (observational cohort study)
06
A 2023 peer-reviewed study found that site-initiated recruitment tools (digital referrals and patient matching) increased screening-to-enrollment conversion rates by 22%
07
A 2021 study in Clinical Pharmacology & Therapeutics found that protocol non-adherence can bias efficacy estimates, with observed adherence rates varying widely across studies
08
A 2021 study estimated that site selection and activation delays add a median of 4 months to trial start time for multicenter studies
09
A 2020 paper reported that data query cycles averaged 45 queries per 100 CRFs in typical operations, indicating measurable downstream workload in clinical data management
10
A 2021 cohort analysis found that trials with stronger site investigator engagement achieved a higher enrollment rate, with an observed percentage increase reported in the study
Interpretation
Performance Metrics Interpretation
Across Performance Metrics, randomized and implementation evidence shows that inefficiencies and process frictions are persistent, with protocol deviations reported in 50%+ of trials from 2017 to 2022 alongside improvements like 48% faster data entry with centralized eSource and a 22% rise in screening to enrollment from site initiated recruitment tools.
06 · Category
Cost Analysis3 stats
01
A 2019–2021 study reported that centralized monitoring approaches reduced the number of monitoring visits by 25% on average (reported in the publication)
02
A 2023 analysis reported that using eTMF reduced documentation retrieval time by 60% compared with paper-based systems in a controlled evaluation
03
In a 2022 paper, electronic trial master file (eTMF) adoption was associated with 2–3x faster responses to audit readiness requests (quantified time savings)
Interpretation
Cost Analysis Interpretation
Across cost analysis evidence from 2019 to 2023, centralized monitoring cut monitoring visits by 25%, eTMF use reduced documentation retrieval time by 60%, and eTMF adoption enabled 2 to 3 times faster audit readiness responses, together showing that digitizing and centralizing trial operations can substantially lower trial operating costs.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Clinical Trial Statistics. Gitnux. https://gitnux.org/clinical-trial-statistics
MLA
Julian Richter. "Clinical Trial Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-trial-statistics.
Chicago
Julian Richter. 2026. "Clinical Trial Statistics." Gitnux. https://gitnux.org/clinical-trial-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)